Tenax Therapeutics, Inc.

Informe acción NasdaqCM:TENX

Capitalización de mercado: US$15.3m

Tenax Therapeutics Dirección

Dirección controles de criterios 4/4

We currently do not have sufficient information about the CEO.

Información clave

Chris Giordano

Chief Executive Officer (CEO)

US$644.8k

Compensación total

Porcentaje del salario del CEO62.9%
Permanencia del CEO3.3yrs
Participación del CEOn/a
Permanencia media de la dirección3.3yrs
Promedio de permanencia en la Junta Directiva3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20
Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Giordano en comparación con los beneficios de Tenax Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$645kUS$405k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$667kUS$386k

-US$11m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$11m

Dec 31 2021US$861kUS$183k

-US$32m

Compensación vs. Mercado: Chris's total compensation ($USD644.77K) is about average for companies of similar size in the US market ($USD655.65K).

Compensación vs. Ingresos: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Giordano (50 yo)

3.3yrs

Permanencia

US$644,770

Compensación

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77ksin datos
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Lawrence Hoffman
Interim Chief Financial Officerless than a yearsin datossin datos
Doug Randall
Executive Vice President of Commercial & Business Operationsno datasin datossin datos
Douglas Hay
Senior Vice President of Regulatory Affairsno datasin datossin datos

3.3yrs

Permanencia media

69yo

Promedio de edad

Equipo directivo experimentado: TENX's management team is considered experienced (3.3 years average tenure).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Christopher Giordano
CEO, President & Director3.3yrsUS$644.77ksin datos
Stuart Rich
Chief Medical Officer & Director3.8yrsUS$481.22k0.043%
$ 6.5k
Gerald Proehl
Independent Chairman10.6yrsUS$88.50k0.049%
$ 7.5k
Michael Davidson
Independent Director3.8yrsUS$57.50k0.085%
$ 12.9k
Daniel Burkhoff
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrssin datossin datos
Declan Doogan
Independent Director3.8yrsUS$48.50k0.067%
$ 10.2k
Robyn Hunter
Independent Director2.8yrsUS$65.00k0%
$ 0
June Almenoff
Independent Director3.8yrsUS$59.50k0%
$ 0
Sanjiv Shah
Member of PH-Left Heart Disease Scientific Advisory Board6.8yrssin datossin datos
Barry Borlaug
Member of PH-Left Heart Disease Scientific Advisory Board4.8yrssin datossin datos
Robert Frantz
Member of PAH Scientific Advisory Boardno datasin datossin datos
Anna Hemnes
Member of PAH Scientific Advisory Boardno datasin datossin datos

3.8yrs

Permanencia media

67yo

Promedio de edad

Junta con experiencia: TENX's board of directors are considered experienced (3.8 years average tenure).